Across TCGA pan-cancer cohorts, TASP1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TASP1 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TASP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TASP1 expression acts as an unfavorable survival marker.
SKCM and PRAD are the cancer types where TASP1 Mutation most reproducibly stratifies survival.